PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
56.85%
Some net income increase while AGEN is negative at -13.81%. John Neff would see a short-term edge over the struggling competitor.
-0.49%
Both reduce yoy D&A, with AGEN at -1.09%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-97.78%
Negative yoy SBC while AGEN is 2.96%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
251.75%
Slight usage while AGEN is negative at -100.00%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
214.04%
AP growth well above AGEN's 280.92%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-132.83%
Both reduce yoy usage, with AGEN at -100.00%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
No Data
No Data available this quarter, please select a different quarter.
28.81%
Operating cash flow growth 1.25-1.5x AGEN's 21.06%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.00%
We cut debt repayment yoy while AGEN is 56.33%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.